The mission details of the funder are not explicitly provided in the given description.
The ADDF grant program aims to catalyze the discovery and development of drugs, biological therapies, and diagnostics for Alzheimer’s disease and associated dementias. Specific areas of interest include translational research for drug development, IND-enabling studies, early-stage clinical trials for new and repurposed drugs, and the development of various biomarkers. Additionally, the program supports epidemiological studies and comparative effectiveness research to understand how different drug choices could influence the risk of dementia. The Prevention Pipeline RFP focuses on studying and reducing cognitive decline and dementia risk through approaches like clinical trials and epidemiology, targeting conditions linked to increased dementia risk. The grant also emphasizes novel drug mechanisms related to aging biology and other innovative therapeutic areas, including epigenetics, inflammation, and neuroprotection, among others.